



PRESS RELEASE MARCH 27th 2012

MOBERG DERMA AND PHARMAPLAN SIGN AGREEMENT FOR NALOX[™]/EMTRIX[®] IN SOUTH AFRICA

Moberg Derma AB (STO:MOB) has entered into a distribution agreement with Pharmaplan (Pty) Ltd. for Nalox[™]/Emtrix[®] – for discolored and damaged nails caused by nail fungus (onychomycosis) or nail psoriasis. Under the agreement Pharmaplan is granted exclusive rights to market and sell Nalox[™]/Emtrix[®] in South Africa. Moberg Derma assumes production and supply responsibility.

“The agreement is part of our international commercialization of Nalox[™]/Emtrix[®]. We are looking forward to make the product available to the patients in South Africa through the cooperation with Pharmaplan”, says Peter Wolpert, President and CEO of Moberg Derma.

About Nalox[™] and nail diseases

Nalox[™] is a topical treatment used to treat nail disease. Launched in the Nordic region in autumn 2010, it quickly became market leader. Nalox[™] is a prescription free, over-the-counter product sold under the name Emtrix[®] in certain markets and under the name Kerasal[®] Nail in the U.S. Safety and efficacy have been demonstrated in several clinical studies including more than 600 patients. Nalox[™] has a unique and rapid mechanism of action which brings visible improvements within 2-4 weeks of treatment. Nail fungus is the most common nail disease and afflicts approximately 10% of the general population and increasing with age. The estimated global market potential exceeds USD 1 billion. The untapped potential is significant since many patients remain untreated. It is generally recognized that there is a need for new efficacious and safe topical treatments.

For further information, please contact:

Peter Wolpert, President and CEO

Telephone: +46 8 522 307 00

Mobile: +46 735 71 35

E-mail: peter.wolpert@mobergderma.se

Magnus Persson, IR

Mobile: +46 73-355 26 01

E-mail: magnus.persson@mobergderma.se

About this information

Moberg Derma discloses the information provided herein pursuant to the Securities Markets Act and/or the Financial Instruments Trading Act. The information was submitted for publication on at 08:30 am (CET) on March 27th, 2012.

About Moberg Derma

Moberg Derma AB (publ), based in Stockholm, develops patented topical pharmaceuticals for the treatment of common disorders through the use of innovative drug delivery. The company's products are based on proven compounds, which reduce time to market, development costs and risk. Moberg Derma's first product Nalox[™]/Emtrix[®] - for nail disorders - became the Nordic market leader directly after launch in autumn 2010 and international launch is ongoing. The portfolio includes approved and launched products to projects in the preclinical and clinical phase. The company began operations at the Karolinska Institute in Stockholm in 2006. The share of Moberg Derma is quoted on the Small Cap list of the NASDAQ OMX Nordic Exchange Stockholm. For further information, please visit: www.mobergderma.se